USFDA inspection at Indore lab finds 4 observations

Regulatory & Legal View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹137.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+0.3% vs market

Healthcare Service Provider peers, median of 28sector+0.0%+0.5% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.5 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5+0.3+0.3+0.0+0.5

Next day

+4.9-0.2+5.1-0.3+5.2

+10.0+0.4+9.6+0.4+9.6

+9.5+0.2+9.3-0.3+9.8

+7.7+0.5+7.2+0.8+6.9

+5.8+0.8+5.1+1.6+4.3

+15.9-0.8+16.7+1.2+14.7

15d

+45.9-2.1+48.1-0.2+46.1

+46.0+0.2+45.8+1.4+44.6

+56.2-9.2+65.4-8.9+65.1

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 28Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

USFDA inspected Choksi Laboratories central lab in Indore from Aug 17-20, 2026, and issued 4 observations. The company is addressing them and will respond within the required timeframe, reaffirming commitment to USFDA compliance.

Likely market impact

Four observations may require corrective action. Short-term stock pressure possible if escalations follow, though such inspections are common for labs.